|
CN108697666A
|
|
Combination treatment for treating oophoroma
|
|
AU2016219497A1
|
|
Combination therapy of Hsp90 inhibitors and PD-1 inhibitors for treating cancer
|
|
WO2016094341A1
|
|
Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer
|
|
US2017136085A1
|
|
Targeted therapeutics
|
|
WO2015171973A1
|
|
Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitory compound based on chemosensitive status
|
|
WO2015153866A1
|
|
Cancer therapy with ganetespib and an egfr inhibitor
|
|
WO2015143004A1
|
|
Targeted therapeutics
|
|
WO2015134464A2
|
|
Targeted therapeutics
|
|
WO2015116774A1
|
|
Targeted therapeutics
|
|
WO2015109218A1
|
|
Targeted cancer treatment by hsp90 inhibitors ganetespib and nvp-auy922
|
|
WO2015066053A2
|
|
Targeted therapeutics
|
|
AU2014268690A1
|
|
Specific cancer treatment regimens with ganetespib
|
|
AU2013331070A1
|
|
Treating polycystic kidney disease with HSP90 inhibitory compounds
|
|
WO2013173436A1
|
|
Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
|
|
US2015099721A1
|
|
Treating cancer with hsp90 inhibitory compounds
|
|
WO2013170182A1
|
|
Treating cancer with an hsp90 inhibitory compound
|
|
AU2013204588A1
|
|
Vinyl-Phenyl Derivatives For Inflammation and Immune-Related Uses
|
|
WO2013152206A1
|
|
Novel triazole compounds that modulate hsp90 activity
|
|
AU2013239663A1
|
|
Triazole derivatives as HSP90 inhibitors
|
|
AU2013201925A1
|
|
Phenyl and Pyridyl Compounds For Inflammation and Immune-Related Uses
|
